Status | Study |
RECRUITING |
Study Name: Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis Condition: Idiopathic Pulmonary Fibrosis Date: 2023-10-18 Interventions: PLN-74809 |
RECRUITING |
Study Name: The Effect of N115 on Coughing in IPF Patients Condition: Idiopathic Pulmonary Fibrosis Date: 2023-09-07 Interventions: The product is a 20 mM (0.2%, 2.2 mg/mL) sodium pyruvate nasal spray in 0.9% sodium chloride with 0.02% benzalkonium chloride preservative, pH 7. |
RECRUITING |
Study Name: A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis Condition: Idiopathic Pulmonary Fibrosis Date: 2023-08-15 Interventions: Specified dose on specified days |
RECRUITING |
Study Name: Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis Condition: Idiopathic Pulmonary Fibrosis Date: 2023-07-26 Interventions: 100 mg daily by mouth for 3 weeks This drug inhibits a protein (Bcl-2) that protects cells from undergoing programmed cell death. |
RECRUITING |
Study Name: Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis Condition: Idiopathic Pulmonary Fibrosis Date: 2023-07-26 Interventions: 100 mg daily by mouth for 3 weeks This drug inhibits a protein (Bcl-2) that protects cells from undergoing programmed cell death. |
RECRUITING |
Study Name: A Study to Investigate Leramistat in Patients With IPF Condition: Idiopathic Pulmonary Fibrosis Date: 2023-06-22 Interventions: Drug: Leramistat |
COMPLETED |
Study Name: Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients Condition: Idiopathic Pulmonary Fibrosis Date: 2023-05-15 Interventions: Nintedanib |
RECRUITING |
Study Name: A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease Condition: Idiopathic Pulmonary Fibrosis Date: 2023-03-14 Interventions: Vixarelimab will be administered as per the schedule specified in the respective arms. |
COMPLETED |
Study Name: Dose Reduction and Discontinuation With Anti-Fibrotic Medications Condition: Idiopathic Pulmonary Fibrosis Date: 2023-03-09 Interventions: Pirfenidone |
RECRUITING |
Study Name: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis Condition: Idiopathic Pulmonary Fibrosis Date: 2023-01-03 Interventions: Orally via a tablet. |